| |
| |
|
| Insider
Information: |
Veness Adam M |
| Relationship: |
SVP, General Counsel a... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
23,423 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$4,186,861 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
23,423 |
|
|
| Total
Value |
$4,186,861 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Acceleron Pharma Inc |
XLRN |
SVP, General Counsel a... |
2021-11-09 |
23,423 |
2019-06-05 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
21 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XLRN |
Acceleron Pharma Inc |
VP, General Counsel and Sec.Of |
• – – |
2019-06-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,631 |
|
- |
|
| XLRN |
Acceleron Pharma Inc |
VP, General Counsel and Sec. |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,100 |
20,731 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
VP, General Counsel and Sec. |
• – – |
2019-07-16 |
4 |
AS |
$40.71 |
$21,902 |
D/D |
(538) |
20,193 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
VP, General Counsel and Sec. |
• – – |
2019-08-09 |
4 |
AS |
$45.00 |
$147,060 |
D/D |
(3,268) |
16,925 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
VP, General Counsel and Sec. |
• – – |
2019-09-10 |
4 |
AS |
$45.18 |
$37,241 |
D/D |
(824) |
16,101 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
VP, General Counsel and Sec. |
• – – |
2020-01-02 |
4 |
AS |
$52.83 |
$22,928 |
D/D |
(434) |
15,667 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
VP, General Counsel and Sec. |
• – – |
2020-01-03 |
4 |
AS |
$51.23 |
$44,826 |
D/D |
(875) |
14,792 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
VP, General Counsel and Sec. |
• – – |
2020-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,369 |
21,161 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2020-04-08 |
4 |
OE |
$27.97 |
$167,820 |
D/D |
6,000 |
27,161 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2020-04-08 |
4 |
AS |
$83.49 |
$513,509 |
D/D |
(6,000) |
21,161 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2020-09-08 |
4 |
AS |
$89.20 |
$179,004 |
D/D |
(2,000) |
19,161 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-01-04 |
4 |
D |
$124.31 |
$117,100 |
D/D |
(942) |
18,219 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-01-05 |
4 |
AS |
$122.46 |
$251,988 |
D/D |
(2,056) |
16,163 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
4,868 |
21,031 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-06-07 |
4 |
D |
$126.69 |
$13,683 |
D/D |
(108) |
20,923 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-09-07 |
4 |
D |
$129.36 |
$75,934 |
D/D |
(587) |
20,336 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-09-08 |
4 |
AS |
$130.00 |
$780 |
D/D |
(6) |
20,330 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-09-09 |
4 |
AS |
$130.00 |
$182,910 |
D/D |
(1,407) |
18,923 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-09-21 |
4 |
AS |
$150.05 |
$997,833 |
D/D |
(6,650) |
18,923 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-09-21 |
4 |
OE |
$30.17 |
$216,624 |
D/D |
6,650 |
25,573 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
SVP, General Counsel and Sec. |
• – – |
2021-11-09 |
4 |
OE |
$29.37 |
$132,165 |
D/D |
4,500 |
23,423 |
0 |
- |
|
21 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
